Published in Ann Intern Med on September 01, 1991
Spironolactone for Pulmonary Arterial Hypertension | NCT01712620
Endothelial Cell Dysfunction in Pulmonary Hypertension | NCT00098072
Neolifes Heart - Pulmonary Hypertension in Preterm Children | NCT02729844
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension | NCT01730092
Registry for Pulmonary Hypertension in China | NCT01417338
Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension | NCT03617458
Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet (2000) 4.42
A novel channelopathy in pulmonary arterial hypertension. N Engl J Med (2013) 4.23
Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med (2009) 3.96
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 2.68
Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med (2013) 2.64
Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.31
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension. Am J Respir Crit Care Med (2009) 2.19
Clinical features of paediatric pulmonary hypertension: a registry study. Lancet (2012) 2.13
Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest (2011) 1.93
Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation (2011) 1.92
Prevalence and prognostic value of left ventricular diastolic dysfunction in idiopathic and heritable pulmonary arterial hypertension. Chest (2011) 1.75
Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol (2007) 1.74
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med (2010) 1.69
Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res (2012) 1.69
Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J (2013) 1.61
Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging (2015) 1.57
Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax (2003) 1.56
Accuracy of noninvasively determined pulmonary artery systolic pressure. Am J Cardiol (2010) 1.56
Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res (2005) 1.55
Traffic-related air pollution and the right ventricle. The multi-ethnic study of atherosclerosis. Am J Respir Crit Care Med (2014) 1.54
Pulmonary vascular wall stiffness: An important contributor to the increased right ventricular afterload with pulmonary hypertension. Pulm Circ (2011) 1.53
Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am (2010) 1.51
Assessing right ventricular function: the role of echocardiography and complementary technologies. Heart (2006) 1.50
Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med (2006) 1.50
Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function. Eur Respir J (2015) 1.46
Right ventricular ejection fraction is better reflected by transverse rather than longitudinal wall motion in pulmonary hypertension. J Cardiovasc Magn Reson (2010) 1.42
Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease. JACC Cardiovasc Imaging (2016) 1.42
Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders. J Heart Lung Transplant (2014) 1.41
Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. Ann Thorac Med (2014) 1.40
Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart (2012) 1.39
Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol (2008) 1.38
Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res (2012) 1.37
Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J (2011) 1.36
Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med (2012) 1.35
Recommendations on the management of pulmonary hypertension in clinical practice. Heart (2001) 1.28
Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2+) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension. Hypertension (2011) 1.27
Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest (2008) 1.27
Response to bosentan in children with pulmonary hypertension. Heart (2005) 1.26
Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest (1996) 1.25
Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart (1998) 1.24
Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest (2013) 1.20
Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol (2010) 1.18
Pulmonary arterial hypertension. Orphanet J Rare Dis (2013) 1.18
Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med (2013) 1.16
Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med (2010) 1.15
Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson (2012) 1.14
The genetic basis of pulmonary arterial hypertension. Hum Genet (2014) 1.14
A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model. Int J Cardiovasc Imaging (2010) 1.11
Upregulation of vascular calcium channels in neonatal piglets with hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2008) 1.11
Pulmonary arterial hypertension: the clinical syndrome. Circ Res (2014) 1.11
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J (2008) 1.10
Circulating miRNAs as potential marker for pulmonary hypertension. PLoS One (2013) 1.10
Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag (2007) 1.09
Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry. Catheter Cardiovasc Interv (2010) 1.09
Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report. Am J Respir Crit Care Med (2010) 1.09
Intravascular ultrasound of the elastic pulmonary arteries: a new approach for the evaluation of primary pulmonary hypertension. Heart (2003) 1.08
Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study. Chest (2016) 1.08
Comparison of bronchopulmonary collaterals and collateral blood flow in patients with chronic thromboembolic and primary pulmonary hypertension. Heart (1997) 1.08
Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res (2013) 1.08
Pulmonary hypertension in bronchopulmonary dysplasia. Semin Perinatol (2013) 1.08
Testosterone negatively regulates right ventricular load stress responses in mice. Pulm Circ (2012) 1.07
Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.06
Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med (2007) 1.06
Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J (2010) 1.06
Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure? Clin J Am Soc Nephrol (2008) 1.05
Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther (2009) 1.05
Novel computed tomographic chest metrics to detect pulmonary hypertension. BMC Med Imaging (2011) 1.05
Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension. Pulm Circ (2011) 1.05
Clinical impact of atrial fibrillation in patients with pulmonary hypertension. PLoS One (2012) 1.03
ACE2 improves right ventricular function in a pressure overload model. PLoS One (2011) 1.03
Methods for measuring right ventricular function and hemodynamic coupling with the pulmonary vasculature. Ann Biomed Eng (2013) 1.03
Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis (2012) 1.03
Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.03
Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ (2015) 1.01
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One (2012) 1.00
Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag (2006) 0.99
Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest (2008) 0.99
Ventricular arrhythmias and autonomic profile in patients with primary pulmonary hypertension. Lung (2004) 0.99
Impact of acute pulmonary embolization on arterial stiffening and right ventricular function in dogs. Ann Biomed Eng (2012) 0.99
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol (2009) 0.98
Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation (2014) 0.98
The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension. Am J Respir Cell Mol Biol (2014) 0.98
Wall shear stress is decreased in the pulmonary arteries of patients with pulmonary arterial hypertension: An image-based, computational fluid dynamics study. Pulm Circ (2012) 0.98
Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson (2012) 0.98
MRI catheterization in cardiopulmonary disease. Chest (2014) 0.97
Right ventricular to left ventricular diameter ratio at end-systole in evaluating outcomes in children with pulmonary hypertension. J Am Soc Echocardiogr (2013) 0.97
Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart (1998) 0.97
Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. Br J Pharmacol (2014) 0.97
Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res (2010) 0.97
Complement C3 deficiency attenuates chronic hypoxia-induced pulmonary hypertension in mice. PLoS One (2011) 0.97
Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. Am J Pathol (2011) 0.97
Current clinical management of pulmonary arterial hypertension. Circ Res (2014) 0.96
Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension. Mol Med (2012) 0.96
A critical role for the protein apoptosis repressor with caspase recruitment domain in hypoxia-induced pulmonary hypertension. Circulation (2011) 0.96
Obesity paradox in group 1 pulmonary hypertension: analysis of the NIH-Pulmonary Hypertension registry. Int J Obes (Lond) (2017) 0.96
Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart (2005) 0.95
Pulmonary hypertension in POEMS syndrome. Haematologica (2012) 0.95
Measuring the quality of medical care. A clinical method. N Engl J Med (1976) 11.68
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
Primary pulmonary hypertension. A national prospective study. Ann Intern Med (1987) 6.80
An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med (1992) 4.74
Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet (2000) 4.42
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07
Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc (1999) 3.32
Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Circulation (1982) 3.23
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation (2000) 2.65
Measuring the quality of medical care: second revision of tables of indexes. N Engl J Med (1980) 2.34
Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest (1997) 2.29
Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation (1996) 2.19
Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J (2009) 2.18
Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation (1989) 2.16
Effect of depth of inhalation on aerosol persistence during breath holding. J Appl Physiol (1973) 2.16
Exercise testing and electron beam computed tomography in the evaluation of coronary artery disease. J Am Coll Cardiol (2000) 2.15
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation (1997) 2.03
Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis (1990) 2.02
Vasodilator therapy for primary pulmonary hypertension in children. Circulation (1999) 2.00
Regional redistribution of blood flow in the mature fetal lamb. Circ Res (1967) 1.99
Long-term outcome of patients with depressed left ventricular function undergoing percutaneous transluminal coronary angioplasty. The NHLBI PTCA Registry. Circulation (1993) 1.98
Results of percutaneous transluminal coronary angioplasty in women. 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation (1993) 1.95
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation (1982) 1.92
Observer agreement in evaluating coronary angiograms. Circulation (1975) 1.92
Flow limitation as a noninvasive assessment of residual upper-airway resistance during continuous positive airway pressure therapy of obstructive sleep apnea. Am J Respir Crit Care Med (1994) 1.85
High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation (1987) 1.85
Electron microscopic alterations at the alveolar level in pulmonary edema. Circ Res (1967) 1.80
Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: a multicenter study. Circulation (1996) 1.76
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J (2004) 1.73
Pressure and volume loading of the right ventricle have opposite effects on left ventricular ejection fraction. Circulation (1995) 1.70
Respiratory adjustment to chronic metabolic alkalosis in man. J Clin Invest (1968) 1.70
American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation (2000) 1.69
American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol (2000) 1.64
Chronic cor pulmonale. Etiology and management. JAMA (1990) 1.63
Propranolol in the treatment of acute myocardial infarction. Effect on myocardial oxygenation and hemodynamics. Circulation (1974) 1.60
Operation Everest II: oxygen transport during exercise at extreme simulated altitude. J Appl Physiol (1985) (1988) 1.60
Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Results from the pilot phase of the Women's Ischemia Syndrome Evaluation (WISE) study. J Am Coll Cardiol (1999) 1.59
Permeability characteristics of cultured endothelial cell monolayers. J Appl Physiol (1985) (1988) 1.58
Hypoxia on the pulmonary circulation. How and where it acts. Circ Res (1976) 1.57
CT-determined pulmonary artery diameters in predicting pulmonary hypertension. Invest Radiol (1984) 1.55
Hemoglobin as a tracer in hemodynamic pulmonary edema. Science (1969) 1.54
Guidelines for perioperative cardiovascular evaluation for noncardiac surgery: an abridged version of the report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Mayo Clin Proc (1997) 1.52
State of the art: chronic cor pulmonale. Am Rev Respir Dis (1976) 1.51
3D coronary reconstruction from routine single-plane coronary angiograms: clinical validation and quantitative analysis of the right coronary artery in 100 patients. Int J Card Imaging (2000) 1.51
Usefulness of electron beam computed tomography scanning for distinguishing ischemic from nonischemic cardiomyopathy. J Am Coll Cardiol (1998) 1.51
Hypothyroidism and primary pulmonary hypertension: an autoimmune pathogenetic link? Ann Intern Med (1993) 1.51
The Veterans Administration Cooperative Study of stable angina: current status. Circulation (1982) 1.49
Calcified left atrial myxoma simulating mitral insufficiency. Hemodynamic and phonocardiographic effects of tumor movement. Circulation (1967) 1.49
Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation (1999) 1.47
Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol (1997) 1.46
Alveolar response to experimental Pneumocystis carinii pneumonia in the rat. Am J Pathol (1980) 1.46
Long-term outcome of patients with incomplete vs complete revascularization after multivessel PTCA. A report from the NHLBI PTCA Registry. Eur Heart J (1998) 1.45
Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. J Am Coll Cardiol (1991) 1.45
Smaller alveolar-arterial O2 gradients in Tibetan than Han residents of Lhasa (3658 m). Respir Physiol (1996) 1.45
Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators. Circulation (2000) 1.45
Balloon angioplasty versus new device intervention: clinical outcomes. A comparison of the NHLBI PTCA and NACI registries. J Am Coll Cardiol (1998) 1.44
Systemic and myocardial hemodynamic responses to relatively small concentrations of carboxyhemoglobin (COHB). Arch Environ Health (1969) 1.44
Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J (2007) 1.44
Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation (1997) 1.43
Responses to constant work rate bicycle ergometry exercise in primary pulmonary hypertension: the effect of inhaled nitric oxide. J Am Coll Cardiol (2000) 1.43
Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation (1995) 1.42
Operation Everest II: preservation of cardiac function at extreme altitude. J Appl Physiol (1985) (1987) 1.42
Prognostic significance of cardiac cinefluoroscopy for coronary calcific deposits in asymptomatic high risk subjects. J Am Coll Cardiol (1994) 1.42
Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology (1998) 1.41
Hermansky-Pudlak syndrome. Pulmonary manifestations of a ceroid storage disorder. Am J Med (1979) 1.40
Myocardial and systemic responses to carboxyhemoglobin. Ann N Y Acad Sci (1970) 1.40
Respiratory failure in disorders of the thoracic cage. Am Rev Respir Dis (1979) 1.39
Right ventricular ischemia and proximal right coronary artery narrowing indicated by exercise ST-segment elevation in lead V1. Am J Cardiol (1989) 1.38
Reversal of the "Pickwickian syndrome" by long-term use of nocturnal nasal-airway pressure. N Engl J Med (1982) 1.38
Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol (1984) 1.36
Ventricular septal defect due to nonpenetrating chest trauma: use of the intra-aortic balloon pump. J Trauma (1987) 1.34
Increased waiting time for liver transplantation results in higher mortality. Transplantation (1997) 1.34
The oxygen consumption of the placenta and foetal membranes in the sheep. J Physiol (1966) 1.34
Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol (1996) 1.31
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J (2002) 1.31
Histamine and interstitial pulmonary edema in the dog. Circ Res (1971) 1.31
The application of Starling's law of capillary exchange to the lungs. J Clin Invest (1967) 1.30
Sensitivity and specificity of assessing coronary bypass graft patency with ultrafast computed tomography: results of a multicenter study. J Am Coll Cardiol (1988) 1.29
BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J (2004) 1.28
Sex differences in early and long-term results of coronary angioplasty in the NHLBI PTCA Registry. Circulation (1985) 1.25
Changes in the practice of percutaneous coronary intervention: a comparison of enrollment waves in the National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry. Am J Cardiol (2001) 1.25
Operation Everest II: pulmonary gas exchange during a simulated ascent of Mt. Everest. J Appl Physiol (1985) (1987) 1.24